Liquidia (LQDA) Stock
Clinical biotech firm developing inhaled medicine delivery systems. Here's the price, business snapshot, and what's worth knowing about Liquidia in July 2026.
Liquidia Corporation (LQDA) is a clinical-stage biopharmaceutical company focused on designing and developing inhaled and targeted medicines using its proprietary PRINT particle-engineering platform. The company aims to improve delivery, dosing consistency and tolerability for respiratory and other conditions through dry-powder and precision-formulated therapies. Investors should be aware that value is heavily tied to clinical trial outcomes, regulatory decisions and potential commercial adoption; revenues may be limited until approval and launch. With a market capitalisation near $2.03 billion, Liquidia can offer upside if its pipeline advances, but also carries significant development, regulatory and commercial risks. Key factors to watch include clinical readouts, partnership agreements, manufacturing scale-up and intellectual-property protection. This summary is for educational purposes and not personalised investment advice — past performance is not a reliable indicator of future results and capital is at risk.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Liquidia Corporation's stock with a target price of $46.44, indicating good value.
Financial Health
Liquidia Corporation is generating solid revenue and cash flow while maintaining a strong profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring LQDA
LNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published: 4 March 2026
Explore BasketInjectable Drug Revolution: What's Next Beyond Pills?
The UK's approval of GSK's long-acting HIV drug marks a pivotal shift from daily pills to less frequent injections. This theme focuses on the pharmaceutical innovators leading the charge in developing and commercializing long-acting therapeutic technologies.
Published: 17 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts and regulatory milestones can materially affect valuation, though outcomes are uncertain and may cause share volatility.
Delivery technology edge
The proprietary PRINT particle-engineering platform aims to improve inhaled drug delivery and consistency; technology progress and IP protection matter.
Commercial and partners
Partnerships and manufacturing scale-up influence commercial prospects, but market uptake, pricing and competition remain material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
